Merck & Company Inc. (NYSE:MRK) traded at a new 12-month high today of $85.96. This new high was reached on below average trading volume as 10.5 million shares traded hands, while the average 30-day volume is approximately 18.3 million shares.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm’s immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm’s sales are generated in the United States.
Merck & Company Inc. share prices have moved between a 12-month high of $85.96 and a low of $70.89 and are now trading 21% above that low price at $85.66 per share.
Merck & Company Inc. has overhead space with shares priced $85.66, or 16.9% below the average consensus analyst price target of $103.04.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com